Department of Digestive Oncology, University Hospital Gasthuisberg, Belgium.
Clin Cancer Res. 2010 Aug 15;16(16):4278-88. doi: 10.1158/1078-0432.CCR-09-3274. Epub 2010 Jun 30.
Hepatocellular carcinomas (HCC) have an unpredictable clinical course, and molecular classification could provide better insights into prognosis and patient-directed therapy. We hypothesized that in HCC, certain microenvironmental regions exist with a characteristic gene expression related to chronic hypoxia which would induce aggressive behavior.
We determined the gene expression pattern for human HepG2 liver cells under chronic hypoxia by microarray analysis. Differentially expressed genes were selected and their clinical values were assessed. In our hypothesis-driven analysis, we included available independent microarray studies of patients with HCC in one single analysis. Three microarray studies encompassing 272 patients were used as training sets to determine a minimal prognostic gene set, and one recent study of 91 patients was used for validation.
Using computational methods, we identified seven genes (out of 3,592 differentially expressed under chronic hypoxia) that showed correlation with poor prognostic indicators in all three training sets (65/139/73 patients) and this was validated in a fourth data set (91 patients). Retrospectively, the seven-gene set was associated with poor survival (hazard ratio, 1.39; P = 0.007) and early recurrence (hazard ratio, 2.92; P = 0.007) in 135 patients. Moreover, using a hypoxia score based on this seven-gene set, we found that patients with a score of >0.35 (n = 42) had a median survival of 307 days, whereas patients with a score of < or =0.35 (n = 93) had a median survival of 1,602 days (P = 0.005).
We identified a unique, liver-specific, seven-gene signature associated with chronic hypoxia that correlates with poor prognosis in HCCs.
肝细胞癌(HCC)的临床病程不可预测,分子分类可以提供更好的预后和针对患者的治疗见解。我们假设在 HCC 中存在某些具有特征性基因表达的微环境区域,这些区域与慢性缺氧有关,会导致侵袭性行为。
我们通过微阵列分析确定了人 HepG2 肝癌细胞在慢性缺氧下的基因表达模式。选择差异表达的基因,并评估其临床价值。在我们的假设驱动分析中,我们将可用的 HCC 患者独立微阵列研究纳入单一分析。三个包含 272 例患者的微阵列研究被用作训练集,以确定最小预后基因集,而最近的 91 例患者的研究则用于验证。
使用计算方法,我们在所有三个训练集中(65/139/73 例患者)确定了七个与预后不良指标相关的基因(在慢性缺氧下表达的 3592 个基因中有七个),在第四个数据集中(91 例患者)进行了验证。回顾性分析,该七基因集与 135 例患者的不良生存(风险比,1.39;P=0.007)和早期复发(风险比,2.92;P=0.007)相关。此外,使用基于该七基因集的缺氧评分,我们发现评分>0.35(n=42)的患者中位生存时间为 307 天,而评分≤0.35(n=93)的患者中位生存时间为 1602 天(P=0.005)。
我们确定了一个与慢性缺氧相关的独特的、肝脏特异性的七基因签名,与 HCC 的不良预后相关。